Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
DeBattista C, Solvason HB, Breen JA, Schatzberg AF. (2000). „Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.”. J Clin Psychopharmacol.20 (2): 274–275. DOI:10.1097/00004714-200004000-00029. PMID10770475.
Zarate CA, Payne JL, Singh J, et al. (July 2004). „Pramipexole for bipolar II depression: a placebo-controlled proof of concept study”. Biol. Psychiatry56 (1): 54–60. DOI:10.1016/j.biopsych.2004.03.013. PMID15219473.
Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. (2002). „Pramipexole in treatment-resistant depression: a 16-week naturalistic study.”. Bipolar Disord.4 (5): 307–314. DOI:10.1034/j.1399-5618.2002.01171.x. PMID12479663.
Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB. (2004). „Pramipexole in treatment-resistant depression: an extended follow-up.”. Depression and Anxiety20 (3): 131–138. DOI:10.1002/da.20038. PMID15549689.
Holman AJ, Myers RR. (2005). „A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.”. Arthritis Rheum.52 (8): 2495–2505. DOI:10.1002/art.21191. PMID16052595.
Schneider Claus, Mierau Joachim (1987). „Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine”. Journal of Medicinal Chemistry30 (3): 494–8. DOI:10.1021/jm00386a009. PMID3820220.
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
DeBattista C, Solvason HB, Breen JA, Schatzberg AF. (2000). „Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.”. J Clin Psychopharmacol.20 (2): 274–275. DOI:10.1097/00004714-200004000-00029. PMID10770475.
Zarate CA, Payne JL, Singh J, et al. (July 2004). „Pramipexole for bipolar II depression: a placebo-controlled proof of concept study”. Biol. Psychiatry56 (1): 54–60. DOI:10.1016/j.biopsych.2004.03.013. PMID15219473.
Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. (2002). „Pramipexole in treatment-resistant depression: a 16-week naturalistic study.”. Bipolar Disord.4 (5): 307–314. DOI:10.1034/j.1399-5618.2002.01171.x. PMID12479663.
Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB. (2004). „Pramipexole in treatment-resistant depression: an extended follow-up.”. Depression and Anxiety20 (3): 131–138. DOI:10.1002/da.20038. PMID15549689.
Holman AJ, Myers RR. (2005). „A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.”. Arthritis Rheum.52 (8): 2495–2505. DOI:10.1002/art.21191. PMID16052595.
Schneider Claus, Mierau Joachim (1987). „Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine”. Journal of Medicinal Chemistry30 (3): 494–8. DOI:10.1021/jm00386a009. PMID3820220.